ManagedCareHemo.com Presents a Clinical Primer: Cost Optimization and Care Coordination for Managed Care and Specialty Pharmacy

Release Date: October 30, 2020
Expiration Date: April 30, 2022
Estimated Time to Complete Activity: 0.75 hours
Compatible with all modern browsers and mobile devices

EXPERT FACULTY


	James T. Kenney, RPh, MBA Founder and President JT Kenney, LLC Click here for biography

	Mark T. Reding, MD Associate Professor of Medicine Director, Center for Bleeding and Clotting Disorders University of Minnesota Medical Center Click here for biography

	John Fox, MD, MHA Chief Boundary Spanner Foxworthy Healthcare Consulting, LLC Click here for biography

TARGET AUDIENCE
This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals

STATEMENT OF NEED/PROGRAM OVERVIEW
Hemophilia presents a unique challenge for managed care organizations and payer professionals: a disease with low incidence that is associated with high costs due to a significant need for health care resources. Successful management of hemophilia is often dependent on highly specialized, coordinated multidisciplinary care among providers, patients, and payers. To effectively address the clinical and administrative barriers to optimal hemophilia management, managed care and specialty pharmacy professionals first require knowledge and competence related to the clinical management of hemophilia, in several key areas including etiology, epidemiology, disease severity, morbidity/clinical manifestations, treatment modalities, and Hemophilia Treatment Centers (HTCs) and the Integrated Care Model.

EDUCATIONAL OBJECTIVES

Describe recent insights into the safety, efficacy, and unique attributes of recently approved and emerging hemophilia treatment options.
Review alignment of recently approved therapies in the current hemophilia treatment algorithm.
Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences.
Apply processes for managed care and specialty pharmacy professionals to improve communication and collaboration with HTCs.

ACCREDITATION

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources, Inc. designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement
Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: 0816-9999-20-167-H01-P
This activity is certified as knowledge-based CPE.

Continuing Nursing Education
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 0.75 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 0.75 contact hours.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Mark T. Reding, MD	Grants/Research Support – Bayer, BioMarin (institutional research support) Consulting fees (ex. Ad boards) – Bayer, CSL Behring, Novo Nordisk, Sanofi Genzyme Speakers’ Bureau – Bayer, CSL Behring, Sanofi Genzyme, Takeda
James T. Kenney, RPh, MBA	No financial interest/relationships relating to the topic of this activity
John Fox, MD, MHA	No financial interest/relationships relating to the topic of this activity

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

*Name of Content Manager*	*Reported Financial Relationship*
MER Content Managers	No financial relationships to disclose.
Impact Education, LLC Staff	No financial relationships to disclose.

DISCLAIMER

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the National Hemophilia Foundation, Medical Education Resources, Impact Education, LLC, and/or BioMarin, CSL Behring, Sanofi Genzyme, Takeda, and uniQure, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT

There are no fees for participating and receiving CME/CE credit for this activity. During the period October 30, 2020 through April 30, 2022, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.